Mineralys Therapeutics, Inc. Common Stock MLYS
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $53.20 (+88.2% upside)
Key Stats
- Today's Range
- $27.71 – $29.40
- 50-Day Range
- $24.95 – $31.11
- 52-Week Range
- $12.59 – $47.65
- Volume
- 1.33 million shs
- Average Volume
- 817K shs
- Market Cap
- $2.50 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.54
- Price / Sales
- —
Short Interest
- Short Interest
- 0.06%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-349,576,000
- Net Margin
- —
- Return on Equity
- -63.45%
- Debt-to-Equity
- 0.00
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Related Stocks
Compare head-to-head: MLYS vs LLY·MLYS vs JNJ·MLYS vs ABBV·MLYS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.